Differences in Clinical and Imaging Features between Asymptomatic and Symptomatic COVID-19 Patients

Table 4

Imaging of asymptomatic carriers and COVID-19 patients in the progression stages [n (%)].

CT features	Progression and peak stage
	Asymptomatic (n = 19)	COVID-19 (n = 27)
Prevalent lesion distribution within lobes
Peripheral area	5(26.32)	3(11.11)	1.80	0.25
Central area	0	0	—	—
Both peripheral and central areas	14(73.68)	24(88.89)	1.80	0.25
Lesion density and interior features
Ground glass opacity	0	0	—	—
Consolidation	0	4(14.81)	3.08	0.13
Both ground glass opacity and consolidation	19(100.0)	23(85.19)	3.08	0.13
Intralobular septal thickening	11(57.89)	15(55.56)	0.02	0.88
Interlobular septal thickening	3(15.79)	8(61.54)	1.18	0.32
Other features
Pleural effusion	1(5.3)	0	1.45	0.41
Enlarged mediastinal lymph nodes	0	0	—	—

Note. Asymptomatic, those who remained asymptomatic; COVID-19, symptomatic COVID-19 patients; the fisher exact test was used.